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Despite the advent of and exciting advances in novel endovascular therapies, t-PA remains
the only proven treatment for acute ischemic stroke to date. Although a variety of rea-
sons likely underlie why past trials of endovascular strategies have been unsuccessful, we
address in this perspective piece one critical unknown for which a solution is undoubt-
edly necessary if future ones are to meet with success: determination and selection of
patients that are “just right” for endovascular treatments, or the Goldilocks dilemma. Key
clinical criteria highlighted in past trials may help provide a solution to this critical prob-
lem. However, for them to do so, we propose that they must be applied in service of
a model that accounts for the nuanced, dynamic nature of acute ischemic stroke better
than the prevailing “time is brain” model. We provide and examine three clinical cases to
illustrate this proposal towards solving the Goldilocks dilemma and advancing treatment in
acute ischemic stroke. Further, we address our field’s ongoing challenge and mission in the
meantime to best care for the “not-so-right” patients, by far the majority of the affected
stroke population.
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The introduction of intravenous tissue plasminogen activator
(t-PA) heralded a sea change in the management of acute ischemic
stroke (AIS). For the first time ever, a medical therapy for acute
stroke was proven effective in reducing long-term impairment
(1). Since that landmark event nearly two decades ago, the AIS
field has witnessed the exciting development of novel endovascu-
lar strategies and heightened hopes of potentially improving upon
t-PA’s clinical efficacy (2–7). The Goldilocks dilemma, or finding
the ideal patient who is “just right,” remains the most formidable
challenge in establishing new therapies for AIS.
Unfortunately, as of yet, no endovascular method has demon-
strated itself more clinically effective than t-PA either in head-
to-head comparison or in combination with it (5–7). Why is this?
This question is an undoubtedly challenging and complex one, but
also an undoubtedly necessary one to answer. Indeed, continued
progress in AIS treatment and any potential role that endovas-
cular methods may play in it rests in the balance. We address
the Goldilocks dilemma as a key unsolved piece of this larger
problem that has already received a great deal of attention in
the stroke community: identifying the ideal patients and enrolling
them in clinical trials seeking to prove efficacy of endovascular
treatments.
The recent disappointing outcomes in related trials are a reflec-
tion not necessarily of flawed endovascular therapies, but, rather,
of flawed selection of candidates likely to benefit from them.
We also propose that improvement of the theoretical framework
of ischemic stroke on which the criteria for determination of
“just right” trial-eligibility is based may allow future trials to
finally achieve success. Finally, we emphasize that, although our
Goldilocks search for the “just right” acute stroke patient is neces-
sary for future improvement in care, we must not be distracted and
neglect our primary mission to care for all stroke patients includ-
ing those “not-so-right” – by far, the vast majority for whom we
neurointensivists and neurohospitalists currently provide acute
stroke care.
THE “JUST RIGHT” RECIPE: AGE, SYMPTOM SEVERITY, AND
EVENT DURATION
Despite disappointing outcomes, multiple studies within the acute
stroke trial literature have nevertheless proven informative. For
one, they have identified and highlighted three clinical parame-
ters that repeatedly and reliably impact stroke outcome regardless
of intervention: patient age, symptom severity (NIHSS score), and
event duration (time). As a result of their clinically predictive value,
the stroke community has heavily weighted its determination of
endovascular eligibility on these criteria. Strokes of higher severity
(NIHSS score>10 and/or consistent with a large-vessel occlusion),
shorter duration (<4.5 h), and in younger patients (<80 years)
have been preferred for trial selection. On the other hand, those
of lower severity and longer duration especially in older patients
have been considered less preferred for enrollment. At first glance,
this inclusion/exclusion “just right” criterion appears reasonable
especially in consideration of its reflection of and adherence to
our field’s current prevailing theoretical framework of ischemia:
that is, ischemic burden is a direct, absolute function of time, and
hence, “time is brain.” However, if this set of criteria and model
of ischemia that it reflects really do offer a best determination
of “just right” endovascular candidacy, then why have our tri-
als not proven this so? The answer certainly cannot entirely lay
in device or operator limitation or inadequacy. Completed trials
have demonstrated that a variety of endovascular therapies and
their operators have consistently yielded revascularization success
rates higher than those of t-PA alone particularly for large-vessel
occlusions (5, 8, 9). Furthermore, they have achieved these rates
without compromising safety (4, 8, 9). Additionally, if these criteria
and model do select the patients that really are “just right,” why do
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these patients, more often than not, require the most intensive and
extended hospital stroke care? If they were truly the best candidates
for these therapies, should these patients not respond accordingly,
and expectedly require less intensive care and shorter hospital
stays than their counterparts who were“not-so-right?”Such results
provide need to search deeper to understand and explain this puz-
zling disconnection between excellent revascularization outcomes
and poor clinical ones for acute stroke endovascular treatments.
TIME IS BRAIN: A DEAD-END IN THE GOLDILOCKS DILEMMA
We consequently direct our attention once again to the “just right”
clinical parameters and “time is brain” model of ischemia that
provides the basis for their use in determination of endovascular
eligibility. In aggregate, age, NIHSS score, and time provide a pre-
treatment clinical snapshot that reflects a highly dynamic interplay
between baseline health including chronic co-morbidities and
acute cerebrovascular pathophysiology. As a real-time estimation
of the interaction between acute and chronic illness, these fac-
tors provide only that and no more: a generic, over-simplified
estimation of active disease. Despite that these factors are clini-
cally generic, we support that they are nevertheless informative
and carry utility in the determination of endovascular therapeutic
eligibility in acute stroke.
However, this criterion’s application in service of an inadequate
model of ischemia has led to an unintentional bias in selection of
candidates unlikely to benefit from endovascular treatment and,
hence, has resulted in poor trial outcomes. “Time is brain” empha-
sizes a directly proportional, absolute dependence of mounting
ischemia on elapsed time over other contributing factors. In real-
ity, however, the exact milieu of pathophysiology at play in active
ischemia is varied, patient-specific and state-dependent: in other
words, a highly complex, dynamic process for which an overly
simplified model like “time is brain” cannot fully account.
THE “JUST RIGHT” DISEASE STATE: ACUTE STROKE CASE
ILLUSTRATIONS
Let us examine eligibility determination for endovascular treat-
ment in three theoretical cases of acute large-vessel occlusive
stroke. The first candidate is a younger patient with a severe stroke
of longer duration: within the current framework of eligibility, a
poor candidate for endovascular therapy. This patient’s current
clinical picture signifies a sizable load of active ischemia sustained
over a relatively short period of time. Consequently, it indicates a
reduced capacity to tolerate and withstand acute injury of at-risk
tissue without symptomatology; and, is reflective of an underly-
ing lack of preexisting disease-mitigating factors, and/or presence
of high burden of chronic morbidities, and/or their compounded
effects (i.e., peripheral vascular, collateral, and cardiac function
statuses). As a result, this patient’s active disease state is not only
severe, but also poorly amenable to preserving penumbral tissue
and, therefore, salvaging endovascular therapies which target it.
The second theoretical candidate is a younger patient with a
severe stroke of shorter duration: within the prevailing “time is
brain” paradigm of acute stroke treatment, an excellent candidate
who appears “just right” for endovascular therapy. However, in
consideration of the related pathophysiology driving his clinical
status, we argue that this patient is not only a poor candidate, but,
perhaps, even a worse one than the first case. In similar fashion
to the first example, this patient’s current clinical state signifies a
significant load of active disease. However, more importantly, it
has been sustained in an even shorter period of time. This active
disease state therefore indicates a profoundly more diminished
capacity to tolerate and withstand acute ischemia, and likely is the
result of a more pronounced presence of chronic co-morbidities
and/or absence of disease-mitigating factors. Consequently, this
patient’s active disease state is, in actuality, even more severe; even
less favorable to penumbral preservation; and, therefore, even less
amenable to salvaging therapies than the first candidate’s.
The final theoretical case is an older patient with a stroke of
mild severity and longer duration: by currently applied eligibil-
ity guidelines, another relatively poor candidate for endovascular
therapy. But, in consideration of the state of active disease that
has resulted in this patient’s clinical status, we argue that one
should consider him not only a good candidate, but, in fact, as
the true “just right” candidate of the three considered. In con-
trast to the first two examples of large-vessel occlusive stroke, this
patient’s current clinical state reflects a minimal load of ischemia
but a large area of penumbra preserved despite, strikingly, a longer
duration of acute illness. This active disease state consequently
indicates an inherently better capacity to tolerate and withstand
acute ischemia, and likely is the result of a notable absence of
chronic co-morbidities and/or presence of disease-mitigating fac-
tors. Consequently, this patient’s active disease status is not only
fundamentally different than those of the former cases; but, as a
result, also more amenable to endovascular rescue therapies.
NEXT STEPS: “NOT-SO-RIGHT” MAY BE “JUST RIGHT”
These theoretical case examples that fall along a continuum of age,
stroke severity, and duration illustrate our contention that these
strong predictors of acute stroke clinical outcome do in fact have
potential utility in determining which patients are “just right” for
endovascular treatments. However, we propose that our field’s cur-
rently favored model of ischemia, “time is brain,” is an inadequate
oversimplification of the complex, dynamic pathophysiology in
acute stroke. As a consequence, its promotion has led uninten-
tionally to a misinterpretation of these three clinical parameters;
subsequent selection bias toward “not-so-right” trial candidates;
and ultimately continued stasis in the progress of acute stroke
therapy. Therefore, we argue for its replacement with a theoretical
framework that better encapsulates and accounts for the dynamic,
nuanced complexity of the active ischemic disease state. In sup-
port, we provide as a basis for these clinical predictors a framework
of ischemia that accounts for the global state of pathophysiol-
ogy during acute stroke: one that incorporates stroke severity and
duration not as independent factors, but as interactive and com-
pounding contributors along a spectrum of active disease states.
Indeed, we must be mindful that although severity and dura-
tion undoubtedly influence clinical outcomes, so too do a host
of other exacerbating and mitigating factors that fall under the
umbrella of the active disease state and influence tissue ischemia
and viability.
Accordingly, we should give pause to consider whether there
may be multiple or, unfortunately, no patients that are “just right”
for endovascular therapies. Both possibilities suggest that such a
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Goldilocks search may be unjustified and not worthwhile. Indeed,
the vast majority of stroke patients that require our acute care in
the hospital are overwhelmingly “not-so-right” precisely because
they represent a broad continuum of active disease states across
the myriad of interactive acute and chronic illnesses that can
clinically declare themselves as acute cerebrovascular pathology.
If we desire to advance the field of acute stroke and its treat-
ments, it is imperative that we not lose sight of this fact. It begs
us to remain humble, open-minded, and open-hearted to the
notion that our current understanding of acute stroke is still rel-
atively superficial. And with that acceptance comes a hope that,
with continued improvement in our understanding, we be able
to call fewer and fewer patients “not-so-right” in the future. To
this end, we propose that a more nuanced framework of acute
ischemia replace our field’s current one to allow for improved
interpretation of valid clinical criteria and determination of eli-
gibility for endovascular treatments in acute stroke trials. Such
a step gives promise that our Goldilocks search will continue
and ultimately, hopefully, identify the ideal acute stroke patient:
one whose acute stroke may be small in severity or even long
in duration, but whose active disease state, regardless, is just
right.
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